AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001F83

The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts

Identifieur interne : 001F83 ( PascalFrancis/Corpus ); précédent : 001F82; suivant : 001F84

The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts

Auteurs : L. Peyrin-Biroulet ; A. Oussalah ; X. Roblin ; M. P. Sparrow

Source :

Alimentary pharmacology & therapeutics [ 0269-2813 ] ; 2011.

RBID : Pascal:11-0118501

Descripteurs français

Pascal (Inist)
- Azathioprine, Entérite de Crohn, Gestation, Femelle, Postopératoire, Monde, Enquête, Immunodépresseur.

English descriptors

KwdEn :
- Azathioprine, Crohn disease, Female, Immunosuppressive agent, Postoperative, Pregnancy, Survey, World.

Abstract

Background Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients. Aim To perform a worldwide survey for evaluating the extent to which gastroenterologists who are experts in the field of IBD are utilising thiopurines during pregnancy and in the post-operative setting in Crohn's disease. Methods This was a Web-based cross-sectional, statement-based survey, which was conducted among experts who have published at least once in the field of thiopurines in IBD. Results Between 20 December 2009 and 9 April 2010, 175 questionnaires were received. The median number of IBD patients per physician per year was 400 (IQR 25-75th, 188-600) and the total number of IBD patients followed by all responders was 82 379. In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administrate azathioprine during pregnancy. After ileocecal resection for Crohn's disease, 39% of physicians initiate azathioprine only in high-risk patients, 28% of practitioners prescribe azathioprine according to endoscopic evaluation, 20% of gastroenterologists systematically initiate azathioprine and 13% have a different attitude. Condusions Almost 9 of 10 physicians continue azathioprine throughout pregnancy. About 7 of 10 physicians prescribe azathioprine in the post-operative setting according to the European Crohn's and Colitis Organisation recommendations, whereas one-fifth of practitioners systematically initiate azathioprine after surgery.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0269-2813`
A03		`1`		`@0 Aliment. pharmacol. ther.`
A05				`@2 33`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts`
A11	`01`	`1`		`@1 PEYRIN-BIROULET (L.)`
A11	`02`	`1`		`@1 OUSSALAH (A.)`
A11	`03`	`1`		`@1 ROBLIN (X.)`
A11	`04`	`1`		`@1 SPARROW (M. P.)`
A14	`01`			`@1 Inserm U954, Henri Poincaré University Nancy 1 @2 Vandoeuvre-lès-Nancy @3 FRA @Z 1 aut. @Z 2 aut.`
A14	`02`			`@1 Department of Hepato-Gastroenterology, University Hospital of Nancy @2 Vandoeuvre-lès-Nancy @3 FRA @Z 1 aut. @Z 2 aut.`
A14	`03`			`@1 Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne @2 Saint-Etienne @3 FRA @Z 3 aut.`
A14	`04`			`@1 Department of Gastroenterology, The Alfred Hospital @2 Melbourne, Vic. @3 AUS @Z 4 aut.`
A20				`@1 707-713`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21831 @5 354000193665340090`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 11-0118501`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Alimentary pharmacology & therapeutics`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Background Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients. Aim To perform a worldwide survey for evaluating the extent to which gastroenterologists who are experts in the field of IBD are utilising thiopurines during pregnancy and in the post-operative setting in Crohn's disease. Methods This was a Web-based cross-sectional, statement-based survey, which was conducted among experts who have published at least once in the field of thiopurines in IBD. Results Between 20 December 2009 and 9 April 2010, 175 questionnaires were received. The median number of IBD patients per physician per year was 400 (IQR 25-75th, 188-600) and the total number of IBD patients followed by all responders was 82 379. In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administrate azathioprine during pregnancy. After ileocecal resection for Crohn's disease, 39% of physicians initiate azathioprine only in high-risk patients, 28% of practitioners prescribe azathioprine according to endoscopic evaluation, 20% of gastroenterologists systematically initiate azathioprine and 13% have a different attitude. Condusions Almost 9 of 10 physicians continue azathioprine throughout pregnancy. About 7 of 10 physicians prescribe azathioprine in the post-operative setting according to the European Crohn's and Colitis Organisation recommendations, whereas one-fifth of practitioners systematically initiate azathioprine after surgery.
C02	`01`	`X`		`@0 002B02H`
C02	`02`	`X`		`@0 002B13B03`
C03	`01`	`X`	`FRE`	`@0 Azathioprine @2 NK @2 FR @5 01`
C03	`01`	`X`	`ENG`	`@0 Azathioprine @2 NK @2 FR @5 01`
C03	`01`	`X`	`SPA`	`@0 Azatioprina @2 NK @2 FR @5 01`
C03	`02`	`X`	`FRE`	`@0 Entérite de Crohn @5 02`
C03	`02`	`X`	`ENG`	`@0 Crohn disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Enteritis Crohn @5 02`
C03	`03`	`X`	`FRE`	`@0 Gestation @5 03`
C03	`03`	`X`	`ENG`	`@0 Pregnancy @5 03`
C03	`03`	`X`	`SPA`	`@0 Gestación @5 03`
C03	`04`	`X`	`FRE`	`@0 Femelle @5 04`
C03	`04`	`X`	`ENG`	`@0 Female @5 04`
C03	`04`	`X`	`SPA`	`@0 Hembra @5 04`
C03	`05`	`X`	`FRE`	`@0 Postopératoire @5 05`
C03	`05`	`X`	`ENG`	`@0 Postoperative @5 05`
C03	`05`	`X`	`SPA`	`@0 Postoperatorio @5 05`
C03	`06`	`X`	`FRE`	`@0 Monde @2 NG @5 06`
C03	`06`	`X`	`ENG`	`@0 World @2 NG @5 06`
C03	`06`	`X`	`SPA`	`@0 Mundo @2 NG @5 06`
C03	`07`	`X`	`FRE`	`@0 Enquête @5 07`
C03	`07`	`X`	`ENG`	`@0 Survey @5 07`
C03	`07`	`X`	`SPA`	`@0 Encuesta @5 07`
C03	`08`	`X`	`FRE`	`@0 Immunodépresseur @5 23`
C03	`08`	`X`	`ENG`	`@0 Immunosuppressive agent @5 23`
C03	`08`	`X`	`SPA`	`@0 Inmunodepresor @5 23`
C07	`01`	`X`	`FRE`	`@0 Thiopurine dérivé @5 37`
C07	`01`	`X`	`ENG`	`@0 Thiopurine derivatives @5 37`
C07	`01`	`X`	`SPA`	`@0 Derivado de la tiopurina @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil digestif @5 38`
C07	`02`	`X`	`ENG`	`@0 Digestive diseases @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato digestivo patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'intestin @5 39`
C07	`03`	`X`	`ENG`	`@0 Intestinal disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Intestino patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Maladie inflammatoire @5 40`
C07	`04`	`X`	`ENG`	`@0 Inflammatory disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Enfermedad inflamatoria @5 40`
N21				`@1 073`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 11-0118501 INIST
ET :	The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts
AU :	PEYRIN-BIROULET (L.); OUSSALAH (A.); ROBLIN (X.); SPARROW (M. P.)
AF :	Inserm U954, Henri Poincaré University Nancy 1/Vandoeuvre-lès-Nancy/France (1 aut., 2 aut.); Department of Hepato-Gastroenterology, University Hospital of Nancy/Vandoeuvre-lès-Nancy/France (1 aut., 2 aut.); Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne/Saint-Etienne/France (3 aut.); Department of Gastroenterology, The Alfred Hospital/Melbourne, Vic./Australie (4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Alimentary pharmacology & therapeutics; ISSN 0269-2813; Royaume-Uni; Da. 2011; Vol. 33; No. 6; Pp. 707-713; Bibl. 21 ref.
LA :	Anglais
EA :	Background Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients. Aim To perform a worldwide survey for evaluating the extent to which gastroenterologists who are experts in the field of IBD are utilising thiopurines during pregnancy and in the post-operative setting in Crohn's disease. Methods This was a Web-based cross-sectional, statement-based survey, which was conducted among experts who have published at least once in the field of thiopurines in IBD. Results Between 20 December 2009 and 9 April 2010, 175 questionnaires were received. The median number of IBD patients per physician per year was 400 (IQR 25-75th, 188-600) and the total number of IBD patients followed by all responders was 82 379. In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administrate azathioprine during pregnancy. After ileocecal resection for Crohn's disease, 39% of physicians initiate azathioprine only in high-risk patients, 28% of practitioners prescribe azathioprine according to endoscopic evaluation, 20% of gastroenterologists systematically initiate azathioprine and 13% have a different attitude. Condusions Almost 9 of 10 physicians continue azathioprine throughout pregnancy. About 7 of 10 physicians prescribe azathioprine in the post-operative setting according to the European Crohn's and Colitis Organisation recommendations, whereas one-fifth of practitioners systematically initiate azathioprine after surgery.
CC :	002B02H; 002B13B03
FD :	Azathioprine; Entérite de Crohn; Gestation; Femelle; Postopératoire; Monde; Enquête; Immunodépresseur
FG :	Thiopurine dérivé; Pathologie de l'appareil digestif; Pathologie de l'intestin; Maladie inflammatoire
ED :	Azathioprine; Crohn disease; Pregnancy; Female; Postoperative; World; Survey; Immunosuppressive agent
EG :	Thiopurine derivatives; Digestive diseases; Intestinal disease; Inflammatory disease
SD :	Azatioprina; Enteritis Crohn; Gestación; Hembra; Postoperatorio; Mundo; Encuesta; Inmunodepresor
LO :	INIST-21831.354000193665340090
ID :	11-0118501

Links to Exploration step

Pascal:11-0118501

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts</title>
<author><name sortKey="Peyrin Biroulet, L" sort="Peyrin Biroulet, L" uniqKey="Peyrin Biroulet L" first="L." last="Peyrin-Biroulet">L. Peyrin-Biroulet</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U954, Henri Poincaré University Nancy 1</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Hepato-Gastroenterology, University Hospital of Nancy</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oussalah, A" sort="Oussalah, A" uniqKey="Oussalah A" first="A." last="Oussalah">A. Oussalah</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U954, Henri Poincaré University Nancy 1</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Hepato-Gastroenterology, University Hospital of Nancy</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Roblin, X" sort="Roblin, X" uniqKey="Roblin X" first="X." last="Roblin">X. Roblin</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne</s1>
<s2>Saint-Etienne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sparrow, M P" sort="Sparrow, M P" uniqKey="Sparrow M" first="M. P." last="Sparrow">M. P. Sparrow</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Gastroenterology, The Alfred Hospital</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0118501</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0118501 INIST</idno>
<idno type="RBID">Pascal:11-0118501</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F83</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts</title>
<author><name sortKey="Peyrin Biroulet, L" sort="Peyrin Biroulet, L" uniqKey="Peyrin Biroulet L" first="L." last="Peyrin-Biroulet">L. Peyrin-Biroulet</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U954, Henri Poincaré University Nancy 1</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Hepato-Gastroenterology, University Hospital of Nancy</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oussalah, A" sort="Oussalah, A" uniqKey="Oussalah A" first="A." last="Oussalah">A. Oussalah</name>
<affiliation><inist:fA14 i1="01"><s1>Inserm U954, Henri Poincaré University Nancy 1</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Hepato-Gastroenterology, University Hospital of Nancy</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Roblin, X" sort="Roblin, X" uniqKey="Roblin X" first="X." last="Roblin">X. Roblin</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne</s1>
<s2>Saint-Etienne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sparrow, M P" sort="Sparrow, M P" uniqKey="Sparrow M" first="M. P." last="Sparrow">M. P. Sparrow</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Gastroenterology, The Alfred Hospital</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Alimentary pharmacology & therapeutics</title>
<title level="j" type="abbreviated">Aliment. pharmacol. ther.</title>
<idno type="ISSN">0269-2813</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Alimentary pharmacology & therapeutics</title>
<title level="j" type="abbreviated">Aliment. pharmacol. ther.</title>
<idno type="ISSN">0269-2813</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Azathioprine</term>
<term>Crohn disease</term>
<term>Female</term>
<term>Immunosuppressive agent</term>
<term>Postoperative</term>
<term>Pregnancy</term>
<term>Survey</term>
<term>World</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Azathioprine</term>
<term>Entérite de Crohn</term>
<term>Gestation</term>
<term>Femelle</term>
<term>Postopératoire</term>
<term>Monde</term>
<term>Enquête</term>
<term>Immunodépresseur</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients. Aim To perform a worldwide survey for evaluating the extent to which gastroenterologists who are experts in the field of IBD are utilising thiopurines during pregnancy and in the post-operative setting in Crohn's disease. Methods This was a Web-based cross-sectional, statement-based survey, which was conducted among experts who have published at least once in the field of thiopurines in IBD. Results Between 20 December 2009 and 9 April 2010, 175 questionnaires were received. The median number of IBD patients per physician per year was 400 (IQR 25-75th, 188-600) and the total number of IBD patients followed by all responders was 82 379. In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administrate azathioprine during pregnancy. After ileocecal resection for Crohn's disease, 39% of physicians initiate azathioprine only in high-risk patients, 28% of practitioners prescribe azathioprine according to endoscopic evaluation, 20% of gastroenterologists systematically initiate azathioprine and 13% have a different attitude. Condusions Almost 9 of 10 physicians continue azathioprine throughout pregnancy. About 7 of 10 physicians prescribe azathioprine in the post-operative setting according to the European Crohn's and Colitis Organisation recommendations, whereas one-fifth of practitioners systematically initiate azathioprine after surgery.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0269-2813</s0>
</fA01>
<fA03 i2="1"><s0>Aliment. pharmacol. ther.</s0>
</fA03>
<fA05><s2>33</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PEYRIN-BIROULET (L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OUSSALAH (A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ROBLIN (X.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>SPARROW (M. P.)</s1>
</fA11>
<fA14 i1="01"><s1>Inserm U954, Henri Poincaré University Nancy 1</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Hepato-Gastroenterology, University Hospital of Nancy</s1>
<s2>Vandoeuvre-lès-Nancy</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne</s1>
<s2>Saint-Etienne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Gastroenterology, The Alfred Hospital</s1>
<s2>Melbourne, Vic.</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>707-713</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21831</s2>
<s5>354000193665340090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0118501</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Alimentary pharmacology & therapeutics</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients. Aim To perform a worldwide survey for evaluating the extent to which gastroenterologists who are experts in the field of IBD are utilising thiopurines during pregnancy and in the post-operative setting in Crohn's disease. Methods This was a Web-based cross-sectional, statement-based survey, which was conducted among experts who have published at least once in the field of thiopurines in IBD. Results Between 20 December 2009 and 9 April 2010, 175 questionnaires were received. The median number of IBD patients per physician per year was 400 (IQR 25-75th, 188-600) and the total number of IBD patients followed by all responders was 82 379. In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administrate azathioprine during pregnancy. After ileocecal resection for Crohn's disease, 39% of physicians initiate azathioprine only in high-risk patients, 28% of practitioners prescribe azathioprine according to endoscopic evaluation, 20% of gastroenterologists systematically initiate azathioprine and 13% have a different attitude. Condusions Almost 9 of 10 physicians continue azathioprine throughout pregnancy. About 7 of 10 physicians prescribe azathioprine in the post-operative setting according to the European Crohn's and Colitis Organisation recommendations, whereas one-fifth of practitioners systematically initiate azathioprine after surgery.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02H</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B13B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Azathioprine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Azathioprine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Azatioprina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Entérite de Crohn</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Crohn disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Enteritis Crohn</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Gestation</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pregnancy</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Gestación</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Femelle</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Female</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Hembra</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Postopératoire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Postoperative</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Postoperatorio</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Monde</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>World</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mundo</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Enquête</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Survey</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Encuesta</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Immunodépresseur</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Immunosuppressive agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Inmunodepresor</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Thiopurine dérivé</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Thiopurine derivatives</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Derivado de la tiopurina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'intestin</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Intestinal disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Intestino patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Maladie inflammatoire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Inflammatory disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad inflamatoria</s0>
<s5>40</s5>
</fC07>
<fN21><s1>073</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 11-0118501 INIST</NO>
<ET>The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts</ET>
<AU>PEYRIN-BIROULET (L.); OUSSALAH (A.); ROBLIN (X.); SPARROW (M. P.)</AU>
<AF>Inserm U954, Henri Poincaré University Nancy 1/Vandoeuvre-lès-Nancy/France (1 aut., 2 aut.); Department of Hepato-Gastroenterology, University Hospital of Nancy/Vandoeuvre-lès-Nancy/France (1 aut., 2 aut.); Department of Hepato-Gastroenterology, University Hospital of Saint-Etienne/Saint-Etienne/France (3 aut.); Department of Gastroenterology, The Alfred Hospital/Melbourne, Vic./Australie (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Alimentary pharmacology & therapeutics; ISSN 0269-2813; Royaume-Uni; Da. 2011; Vol. 33; No. 6; Pp. 707-713; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Background Although thiopurines are considered safe in humans, they are still pregnancy FDA category D drugs. Prevention of post-operative recurrence is a challenge in clinical practice in Crohn's disease. The European Crohn's and Colitis Organisation consensus states that thiopurines should be considered in high-risk patients. Aim To perform a worldwide survey for evaluating the extent to which gastroenterologists who are experts in the field of IBD are utilising thiopurines during pregnancy and in the post-operative setting in Crohn's disease. Methods This was a Web-based cross-sectional, statement-based survey, which was conducted among experts who have published at least once in the field of thiopurines in IBD. Results Between 20 December 2009 and 9 April 2010, 175 questionnaires were received. The median number of IBD patients per physician per year was 400 (IQR 25-75th, 188-600) and the total number of IBD patients followed by all responders was 82 379. In a pregnant woman with a history of severe Crohn's disease in clinical remission after 1 year on azathioprine, 89% of experts usually continue azathioprine until delivery and 9% of physicians never administrate azathioprine during pregnancy. After ileocecal resection for Crohn's disease, 39% of physicians initiate azathioprine only in high-risk patients, 28% of practitioners prescribe azathioprine according to endoscopic evaluation, 20% of gastroenterologists systematically initiate azathioprine and 13% have a different attitude. Condusions Almost 9 of 10 physicians continue azathioprine throughout pregnancy. About 7 of 10 physicians prescribe azathioprine in the post-operative setting according to the European Crohn's and Colitis Organisation recommendations, whereas one-fifth of practitioners systematically initiate azathioprine after surgery.</EA>
<CC>002B02H; 002B13B03</CC>
<FD>Azathioprine; Entérite de Crohn; Gestation; Femelle; Postopératoire; Monde; Enquête; Immunodépresseur</FD>
<FG>Thiopurine dérivé; Pathologie de l'appareil digestif; Pathologie de l'intestin; Maladie inflammatoire</FG>
<ED>Azathioprine; Crohn disease; Pregnancy; Female; Postoperative; World; Survey; Immunosuppressive agent</ED>
<EG>Thiopurine derivatives; Digestive diseases; Intestinal disease; Inflammatory disease</EG>
<SD>Azatioprina; Enteritis Crohn; Gestación; Hembra; Postoperatorio; Mundo; Encuesta; Inmunodepresor</SD>
<LO>INIST-21831.354000193665340090</LO>
<ID>11-0118501</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F83 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001F83 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:11-0118501
   |texte=   The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts

The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri